OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 LICENSE, CO- DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Palatin Technologies, Inc. and Chemical Works...License, Co-Development and Commercialization Agreement • October 9th, 2014 • Palatin Technologies Inc • Pharmaceutical preparations
ContractLicense, Co-Development and Commercialization Agreement • May 5th, 2020
EX-10.27 2 ptn_ex1027.htm LICENSE, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT Exhibit 10.27 *** OMITTED AND FILED SEPARATELY WITH THE SECURITIES AND EXCHANGE COMMISSION CONFIDENTIAL TREATMENT REQUESTED UNDER 17 C.F.R. SECTION 240.24b-2 LICENSE, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT between Palatin Technologies, Inc. and Chemical Works of Gedeon Richter Plc. This binding agreement was executed on August 29th, 2014 1 LICENSE, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT THIS LICENSE, CO-DEVELOPMENT AND COMMERCIALIZATION AGREEMENT (the “Agreement”), effective as of August 29th, 2014 (the “Effective Date”), is entered between: Palatin Technologies, Inc., a United States company operating under the laws of the United States of America and under the laws of the State of Delaware, with a principal place of business at 4-B Cedar Brook Drive, Cranbury, New Jersey 08512, USA (“Palatin”), and: Chemical Works of Gedeon Richter Plc., a Hungarian company operating under the laws of Hu
